CANC

CANC aims for long-term growth by investing in companies that derive most of their revenue from the field of oncology. This includes large pharmaceutical firms, medical device companies and healthcare service providers whose primary focus is cancer treatment and management. The fund adopts a comprehensive analysis approach, utilizing internal research, external sources, and thematic investing strategies to identify promising investment opportunities within the oncology sector. The portfolio typically consists of 15 to 100 companies that meet minimum market capitalization and trading liquidity requirements. While CANC may hold stocks of companies globally, a substantial portion of its assets are anticipated to be allocated in the US and Europe. Additionally, ESG factors are incorporated in the fund's investment process for smart risk management and return optimization. Being actively managed, the portfolio manager has full discretion to make buy, sell, and hold decisions.